# Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.

> **NCT06320080** · PHASE1 · TERMINATED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 22 (actual)

## Conditions studied

- Advanced Hepatocellular Carcinoma

## Interventions

- **DRUG:** TQB2223 injection
- **DRUG:** Penpulimab Injection

## Key facts

- **NCT ID:** NCT06320080
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-05-30
- **Primary completion:** 2025-11-03
- **Final completion:** 2025-11-03
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06320080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06320080, "Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06320080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*